Shnayder, N.A.,
Grechkina, V.V.,
Khasanova, A.K.,
Bochanova, E.N.,
Dontceva, E.A.,
Petrova, M.M.,
Asadullin, A.R.,
Shipulin, G.A.,
Altynbekov, K.S.,
Al-Zamil, M.,
Nasyrova, R.F. (2023) of therapeutic and
toxic metabolites of VPA in the human body. Thus, VPA is considered a component of disease
Khaliullin, F.A.,
Klen, E.E.,
Nikitina, I.L.,
Pavlov, V.N.,
Rozit, G.A.,
Gaisina, G.G.,
Samorodov, A.V. (2023) IXa is a low-
toxic substance (class 4
toxicity) with a high bioavailability predicted according
Khaliullin, F. A.,
Klen, E. E.,
Nikitina, I. L.,
Pavlov, V. N.,
Rozit, G. A.,
Gaisina, G. G.,
Samorodov, A. V. (2023) IXa is a
low-
toxic substance (class 4
toxicity) with a high bioavailability predicted according